Pharmacoeconomic Guidelines: China Mainland

Country/Region: China Mainland
Published PE Recommendations
China Guidelines for Pharmacoeconomic Evaluations (2020)
PDF in English

Information current as of Thursday, April 22, 2021

Key Features

Type of Guidelines Published PE Recommendations
Title and year of the document China Guidelines for Pharmacoeconomic Evaluations (2020)
Affiliation of authors Peking University, Fudan University, Tianjin University, China Pharmaceutical University, Ministry of Human Resources and Social Security (MHRSS), PLA 306 Hospital, and many others
Purpose of the document Provide scientific basis for researchers to conduct economic analysis of medicines for pricing and reimbursement policy making in China
Standard reporting format included Yes
Disclosure Yes
Target audience of funding/ author's interests Both public and private payers, healthcare industries, clinicians, and research communities
Perspective Primarily society and healthcare systems, followed by payers, health care provider, patients
Indication Primarily approved indications
Target population Both insured and uninsured populations, defined by inclusion and exclusion criteria
Subgroup analysis Yes
Choice of comparator Primarily standard care or conventional treatment
Time horizon Long enough to capture the major costs and outcomes related to the interventions.
Assumptions required Yes
Preferred analytical technique Primarily CUA
Costs to be included Primarily direct medical costs, followed by direct non-medical cost and indirect cost if data available
Source of costs Best available, including data from National Healthcare Security Administation (NHSA), and National Health Commission (NHC)
Modeling Yes, both decision-tree and econometric frameworks
Systematic review of evidences Yes
Preference for effectiveness over efficacy Efficacy should be based on the best available evidence (i.e., the best evidence among the clinical efficacy studies and effectiveness studies). For new drugs, if available and applicable, clinical efficacy data from a randomized controlled trial (RCT) is preferred; for drugs which have been in the market for years, when it is not possible to obtain new efficacy data or data is not applicable, effectiveness data from a real-world study should be used.
Preferred outcome measure Final Endpoints; QALY; WTP
Preferred method to derive utility EQ-5D (EuroQol-5 Dimensions), SF-6D (Short-Form Six-Dimensions), are recommended
Equity issues stated Yes
Discounting costs Base case: 5%; sensitivity analysis: 0-8%
Discounting outcomes Base case: 5%; sensitivity analysis: 0-8%
Sensitivity analysis-parameters and range All assumptions should be subject to sensitivity analysis.
Sensitivity analysis-methods One-way, multi-way, threshold analysis, analysis of extremes, scenario analysis, Monte Carlo simulation
Presenting results Reports both in disaggregated and aggregated form.
Incremental analysis Yes
Total costs vs effectiveness (cost/effectiveness ratio) Yes
Portability of results (Generalizability) Yes, PE study should address the extent to which both the input data and the results can be applied from one setting to another, both domestically and internationally if cross-country data is involved
Financial impact analysis Yes, budget impact analysis is recommended when data is available
Mandatory or recommended or voluntary Voluntary for now to start, expecting to be recommended in a few years


Chinese Pharmaceutical Association, China Society for Pharmacoeconmics and Outcomes Research and ISPOR Beijing Chapter highly contributed to the Guidelines development and the key feature form.
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on Update my browser now